MolMet Figure 6: Higher blood cholesterol and lower fasting blood glucose and insulin in P446L mice on high energy diets.
A-F) Chronic study of P446L mice on HFD: A. Experimental design.
B) Body weight, liver weight and epididymis fat pad weight, (n=7,7).
C) No difference in free-feeding blood glucose and insulin (21 wk, n=7,7) or glucose tolerance (4-wk, GTT, n=9,9).
D) Higher blood cholesterol and liver triglyceride by LL genotype but no difference in blood triglyceride or liver cholesterol (n=6-7).
E) Representative hematoxylin-eosin images showing microvesicular steatosis in LL-genotype.
F) Histopathology scores for steatosis, microvesicular steatosis, lipogranulomas, lobular Inflammation, portal Inflammation and fibrosis showing higher microvesicular steatosis by LL genotype (n=7,7).
G-L) Chronic study of P446L mice on HFHSD: G. Experimental design. H. Body weight, liver weight and higher epididymal fat pad wt by LL genotype, n=11-13.
I) Free feeding blood glucose and insulin and glucose tolerance test (GTT), n=11-14.
J) Lower post-prandial blood glucose (2h food withdrawal) and insulin and inorganic phosphate (Pi) at cull, n=10-14.
K) Higher blood cholesterol in LL genotype but no difference in blood triglycerides or liver triglycerides and cholesterol, n=10-14.
L) Histopathology scores showing higher lipogranuloma and lower fibrosis scores by LL genotype, n=14,13.
M) Representative hematoxylin-eosin images showing lipogranulomas and Sirius red fast green (SRFG) for fibrosis staining.
Categorical data statistical differences was by Chi Square test; other analysis was by t-test #P< 0.05; ##P< 0.01; ### P<0.001 for genotype effect.
MICA: Exploring a new perspective on the mechanism of action of Glucokinase Activators in liver, a preclinical study
Medical Research CouncilFind out more...